9JBV
Structure of Engineered Coagulation Factor VIII with Enhanced Secretion and Coagulation Potential
Entity
| Entity ID | Chain ID | Description | Type | Chain length | Formula weight | Number of molecules | DB Name (Accession) | Biological source | Descriptive keywords |
| 1 | A (A) | Coagulation factor VIII | polymer | 1457 | 167452.5 | 1 | UniProt (P00451) Pfam (PF07732) Pfam (PF07731) Pfam (PF00754) | Homo sapiens (human) | Antihemophilic factor,AHF,Procoagulant component |
Sequence modifications
A: 1 - 764 (UniProt: P00451)
A: 765 - 1457 (UniProt: P00451)
| PDB | External Database | Details |
|---|---|---|
| Pro 15 | Arg 15 | conflict |
| His 44 | Pro 44 | conflict |
| Thr 47 | Ala 47 | conflict |
| Pro 171 | Leu 171 | conflict |
| Asn 232 | Lys 232 | conflict |
| Thr 236 | Met 236 | conflict |
| Gln 247 | Trp 247 | conflict |
| Pro 386 | Ser 386 | conflict |
| Leu 429 | Gln 429 | conflict |
| His 506 | Tyr 506 | conflict |
| Gly 508 | Arg 508 | conflict |
| Met 520 | Phe 520 | conflict |
| Leu 558 | Met 558 | conflict |
| Met 585 | Ile 585 | conflict |
| Pro 622 | Leu 622 | conflict |
| Val 661 | Ile 661 | conflict |
| Pro 746 | Ser 746 | conflict |
| Val 755 | Ala 755 | conflict |
| PDB | External Database | Details |
|---|---|---|
| Pro 782 | Ser 1676 | conflict |
| Glu 784 | Gln 1678 | conflict |
| Lys 786 | Glu 1680 | conflict |
| Phe 793 | Ile 1687 | conflict |
| Gly 806 | Asp 1700 | conflict |
| Lys 901 | Arg 1795 | conflict |
| Arg 984 | His 1878 | conflict |
| Val 1118 | Ala 2012 | conflict |
| Gln 1132 | His 2026 | conflict |
| Lys 1144 | Asn 2038 | conflict |
| Met 1210 | Lys 2104 | conflict |
| Leu 1321 | Phe 2215 | conflict |
| Gln 1332 | Lys 2226 | conflict |
| Leu 1400 | Phe 2294 | conflict |
| Ala 1421 | Ser 2315 | conflict |
| Ala 1439 | Val 2333 | conflict |
| His 1441 | Gln 2335 | conflict |
| Leu 1446 | Met 2340 | conflict |
Sequence viewer
Contents of the asymmetric unit
| Polymers | Number of chains | 1 |
| Total formula weight | 167452.5 | |
| All* | Total formula weight | 167452.5 |






